Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 69,579
Sort by:

E3 Ubiquitin Protein Ligase CBL B (Casitas B Lineage Lymphoma Proto Oncogene b or RING Finger Protein 56 or SH3 Binding Protein CBLB or Signal Transduction Protein CBLB or CBLB or EC 2.3.2.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

E3 Ubiquitin Protein Ligase CBL B (Casitas B Lineage Lymphoma Proto Oncogene b or RING Finger Protein 56 or SH3 Binding Protein CBLB or Signal Transduction Protein CBLB or CBLB or EC 2.3.2.27) Drugs i...

May 2022 40 pages

Ectonucleoside Triphosphate Diphosphohydrolase 1 (NTPDase 1 or Ecto ATP Diphosphohydrolase 1 or Ecto Apyrase or Lymphoid Cell Activation Antigen or CD39 or ENTPD1 or EC 3.6.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ectonucleoside Triphosphate Diphosphohydrolase 1 (NTPDase 1 or Ecto ATP Diphosphohydrolase 1 or Ecto Apyrase or Lymphoid Cell Activation Antigen or CD39 or ENTPD1 or EC 3.6.1.5) Drugs in Development b...

May 2022 45 pages

Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC 1.14.11.29) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Egl Nine Homolog 1 (Hypoxia Inducible Factor Prolyl Hydroxylase 2 or Prolyl Hydroxylase Domain Containing Protein 2 or SM 20 or EGLN1 or EC 1.14.11.29) Drugs in Development by Therapy Areas and Indica...

May 2022 39 pages

Endothelial PAS Domain Containing Protein 1 (Basic Helix Loop Helix PAS Protein MOP2 or Class E Basic Helix Loop Helix Protein 73 or HIF 1 Alpha Like Factor or Hypoxia Inducible Factor 2 Alpha or PAS Domain Containing Protein 2 or EPAS1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Endothelial PAS Domain Containing Protein 1 (Basic Helix Loop Helix PAS Protein MOP2 or Class E Basic Helix Loop Helix Protein 73 or HIF 1 Alpha Like Factor or Hypoxia Inducible Factor 2 Alpha or PAS...

May 2022 43 pages

Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Sta...

May 2022 259 pages

Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein Kinase CAK or CD167a or DDR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein...

May 2022 42 pages

Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 (PRKR Like Endoplasmic Reticulum Kinase or Pancreatic eIF2 Alpha Kinase or EIF2AK3 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 (PRKR Like Endoplasmic Reticulum Kinase or Pancreatic eIF2 Alpha Kinase or EIF2AK3 or EC 2.7.11.1) Drugs in Development by Therapy Areas and I...

May 2022 35 pages

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Drugs in Develop...

May 2022 99 pages

Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46) Drugs in Development by Therapy Areas...

May 2022 38 pages

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC...

May 2022 40 pages

Glycylpeptide N Tetradecanoyltransferase (Myristoyl CoA:Protein N Myristoyltransferase or Peptide N Myristoyltransferase or NMT or EC 2.3.1.97) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Glycylpeptide N Tetradecanoyltransferase (Myristoyl CoA:Protein N Myristoyltransferase or Peptide N Myristoyltransferase or NMT or EC 2.3.1.97) Drugs in Development by Therapy Areas and Indications, S...

May 2022 35 pages

Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 35 pages

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Ind...

May 2022 36 pages

Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 36 pages

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 40 pages

Integrin Alpha M (CD11 Antigen Like Family Member B or CR 3 Alpha Chain or Leukocyte Adhesion Receptor MO1 or Neutrophil Adherence Receptor or CD11b or ITGAM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Integrin Alpha M (CD11 Antigen Like Family Member B or CR 3 Alpha Chain or Leukocyte Adhesion Receptor MO1 or Neutrophil Adherence Receptor or CD11b or ITGAM) Drugs in Development by Therapy Areas and...

May 2022 35 pages

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Drugs in Development by Therapy Areas an...

May 2022 52 pages

Interleukin 18 Receptor 1 (CD218 Antigen Like Family Member A or CDw218a or IL1 Receptor Related Protein or CD218a or IL18R1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 18 Receptor 1 (CD218 Antigen Like Family Member A or CDw218a or IL1 Receptor Related Protein or CD218a or IL18R1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, M...

May 2022 39 pages

Interleukin 2 Receptor Subunit Beta (High Affinity IL 2 Receptor Subunit Beta or Interleukin 15 Receptor Subunit Beta or p70-75 or CD122 or IL2RB) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 2 Receptor Subunit Beta (High Affinity IL 2 Receptor Subunit Beta or Interleukin 15 Receptor Subunit Beta or p70-75 or CD122 or IL2RB) Drugs in Development by Therapy Areas and Indications...

May 2022 58 pages

Interleukin 33 (Interleukin 1 Family Member 11 or IL1F11 or Nuclear Factor From High Endothelial Venules or NFHEV or IL33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 33 (Interleukin 1 Family Member 11 or IL1F11 or Nuclear Factor From High Endothelial Venules or NFHEV or IL33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole...

May 2022 43 pages

Interleukin 6 (B Cell Stimulatory Factor 2 or BSF2 or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Beta 2 or IFNB2 or IL6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 6 (B Cell Stimulatory Factor 2 or BSF2 or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Beta 2 or IFNB2 or IL6) Drugs in Development by Therapy Areas and Indic...

May 2022 53 pages

Interleukin 6 Receptor Subunit Beta (Membrane Glycoprotein 130 or Oncostatin M Receptor Subunit Alpha or Interleukin 6 Signal Transducer or gp130 or CD130 or IL6ST) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Interleukin 6 Receptor Subunit Beta (Membrane Glycoprotein 130 or Oncostatin M Receptor Subunit Alpha or Interleukin 6 Signal Transducer or gp130 or CD130 or IL6ST) Drugs in Development by Therapy Are...

May 2022 37 pages

Isocitrate Dehydrogenase [NADP] Cytoplasmic (Oxalosuccinate Decarboxylase or Cytosolic NADP Isocitrate Dehydrogenase or IDP or NADP(+) Specific ICDH or IDH1 or EC 1.1.1.42) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Isocitrate Dehydrogenase [NADP] Cytoplasmic (Oxalosuccinate Decarboxylase or Cytosolic NADP Isocitrate Dehydrogenase or IDP or NADP(+) Specific ICDH or IDH1 or EC 1.1.1.42) Drugs in Development by The...

May 2022 42 pages

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole...

May 2022 35 pages

Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Drugs in Development by Therapy...

May 2022 57 pages

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Drugs in Development by Therapy Areas and Indications, Stages, MoA, Ro...

May 2022 127 pages

Low Affinity Immunoglobulin Gamma Fc Region Receptor III A (Fc Gamma RIII Alpha or IgG Fc Receptor III-2 or CD16a or FCGR3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Low Affinity Immunoglobulin Gamma Fc Region Receptor III A (Fc Gamma RIII Alpha or IgG Fc Receptor III-2 or CD16a or FCGR3A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mo...

May 2022 40 pages

Lysyl Oxidase Homolog 2 (Lysyl Oxidase Like Protein 2 or Lysyl Oxidase Related Protein 2 or Lysyl Oxidase Related Protein WS9-14 or LOXL2 or EC 1.4.3.13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lysyl Oxidase Homolog 2 (Lysyl Oxidase Like Protein 2 or Lysyl Oxidase Related Protein 2 or Lysyl Oxidase Related Protein WS9-14 or LOXL2 or EC 1.4.3.13) Drugs in Development by Therapy Areas and Indi...

May 2022 37 pages

Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Drugs in Development by Therapy Areas and I...

May 2022 39 pages

Membrane Primary Amine Oxidase (Copper Amine Oxidase or Semicarbazide-Sensitive Amine Oxidase or Vascular Adhesion Protein 1 or HPAO or AOC3 or EC 1.4.3.21) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Membrane Primary Amine Oxidase (Copper Amine Oxidase or Semicarbazide-Sensitive Amine Oxidase or Vascular Adhesion Protein 1 or HPAO or AOC3 or EC 1.4.3.21) Drugs in Development by Therapy Areas and I...

May 2022 43 pages

Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) Drugs in Development by Therapy Areas and Indicati...

May 2022 41 pages

Monoglyceride Lipase (Lysophospholipase Homolog or Lysophospholipase Like or HU K5 or Monoacylglycerol Lipase or MGLL or EC 3.1.1.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Monoglyceride Lipase (Lysophospholipase Homolog or Lysophospholipase Like or HU K5 or Monoacylglycerol Lipase or MGLL or EC 3.1.1.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA...

May 2022 38 pages

Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications,...

May 2022 44 pages

Multidrug Resistance Protein 1 (ATP Binding Cassette Sub Family B Member 1 or P Glycoprotein 1 or CD243 or ABCB1 or EC 7.6.2.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Multidrug Resistance Protein 1 (ATP Binding Cassette Sub Family B Member 1 or P Glycoprotein 1 or CD243 or ABCB1 or EC 7.6.2.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 45 pages

Myotonin Protein Kinase (DM Kinase or DM1 Protein Kinase or Thymopoietin Homolog or Myotonin Protein Kinase A or Myotonic Dystrophy Associated Protein Kinase or DMPK or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Myotonin Protein Kinase (DM Kinase or DM1 Protein Kinase or Thymopoietin Homolog or Myotonin Protein Kinase A or Myotonic Dystrophy Associated Protein Kinase or DMPK or EC 2.7.11.1) Drugs in Developme...

May 2022 44 pages

NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Py...

May 2022 66 pages

NAD Dependent Protein Deacetylase Sirtuin 2 (Regulatory Protein SIR2 Homolog 2 or SIR2 Like Protein 2 or SIRT2 or EC 2.3.1.286) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

NAD Dependent Protein Deacetylase Sirtuin 2 (Regulatory Protein SIR2 Homolog 2 or SIR2 Like Protein 2 or SIRT2 or EC 2.3.1.286) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 39 pages

Natural Cytotoxicity Triggering Receptor 1 (Lymphocyte Antigen 94 Homolog or NK Cell Activating Receptor or Natural Killer Cell p46 Related Protein or CD335 or NCR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Natural Cytotoxicity Triggering Receptor 1 (Lymphocyte Antigen 94 Homolog or NK Cell Activating Receptor or Natural Killer Cell p46 Related Protein or CD335 or NCR1) Drugs in Development by Therapy Ar...

May 2022 40 pages

Nitric Oxide Synthase Inducible (Hepatocyte NOS or Inducible NO Synthase or Peptidyl Cysteine S Nitrosylase NOS2 or NOS Type II or NOS2 or EC 1.14.13.39) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Nitric Oxide Synthase Inducible (Hepatocyte NOS or Inducible NO Synthase or Peptidyl Cysteine S Nitrosylase NOS2 or NOS Type II or NOS2 or EC 1.14.13.39) Drugs in Development by Therapy Areas and Indi...

May 2022 41 pages

NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2 D Activating NK Receptor or CD314 or KLRK1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

NKG2 D Type II Integral Membrane Protein (Killer Cell Lectin Like Receptor Subfamily K Member 1 or NK Cell Receptor D or NKG2 D Activating NK Receptor or CD314 or KLRK1) Drugs in Development by Therap...

May 2022 39 pages

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or Ubiquitously Expressed Nuclear Receptor or LXRB or NR1H2) Drugs in Devel...

May 2022 37 pages

P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y(cyc) or P2Y12 or P2RY12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y(cyc) or P2Y12 or P2RY12) Drugs in Development by Therapy Areas and Indications, Stages,...

May 2022 40 pages

Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial (Cyclophilin D or Cyclophilin F or Mitochondrial Cyclophilin or Rotamase F or PPIF or EC 5.2.1.8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial (Cyclophilin D or Cyclophilin F or Mitochondrial Cyclophilin or Rotamase F or PPIF or EC 5.2.1.8) Drugs in Development by Therapy Areas and Indicati...

May 2022 37 pages

Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or EC 3.1.3.48 or EC 3.1.3.67) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or...

May 2022 35 pages

Platelet Derived Growth Factor Receptor Alpha (Alpha Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member A or Platelet Derived Growth Factor Receptor 2 or CD140a or PDGFRA or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Platelet Derived Growth Factor Receptor Alpha (Alpha Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member A or Platelet Derived Growth Factor Receptor 2 or CD140a or PDGFRA...

May 2022 52 pages

Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member B or Platelet Derived Growth Factor Receptor 1 or CD140b or PDGFRB or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member B or Platelet Derived Growth Factor Receptor 1 or CD140b or PDGFRB o...

May 2022 62 pages

Platelet Glycoprotein 4 (Fatty Acid Translocase or Glycoprotein IIIb or Leukocyte Differentiation Antigen CD36 or PAS4 or Platelet Collagen Receptor or Platelet Glycoprotein IV or Thrombospondin Receptor or CD36) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Platelet Glycoprotein 4 (Fatty Acid Translocase or Glycoprotein IIIb or Leukocyte Differentiation Antigen CD36 or PAS4 or Platelet Collagen Receptor or Platelet Glycoprotein IV or Thrombospondin Recep...

May 2022 37 pages

Filters

Search

Categories

836
28
208
156
143
133
127
93
65,439
803
718
772
123

Publishers

179
1
239
158
389
103
444
148
425
3
202
3
6
1,620
487
76
123
208
111
25
212
1,049
378
23
40
68
472
277
34
29,954
248
501
3,036
1
1
2
3
16
536
361
1
1,357
1,790
60
1,696
8
8,921
2,212
4,495
321
66
3
36
200
29
29
143
42
83
3
281
85
20
6
43
14
1
178
48
359
36
44
10
11
18
168
323
8
3
18
58
901
6
89
12
24
15
1,285
227
128
386
3
74
10
119
228
46
474
26
133
4

Regions

92
58
45
43
41
35
31
30
30
29
28
28
28
26
16
16
14
12
12
10
10
10
9
8
8
8
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
790
495
2
2
2
117
194
102
53
23
704
26
136
526
174
623
64,568

Price

Date

Pages

Offers

1
280
1
1